A Chimpanzee-Origin Adenovirus Vector Expressing the Rabies Virus Glycoprotein as an Oral Vaccine against Inhalation Infection with Rabies Virus

Zhou, Dongming; Cun, Ann; Li, Yan; Xiang, Zhiquan; Ertl, Hildegund C. J.

doi:10.1016/j.ymthe.2006.03.027

Cited by 50 publications

(35 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Error bars were excluded for clarity. vaccination using AdHu5-based vaccine platforms have been shown to confer protection from of a variety of pathogens in the presence of AdHu5 PEI in several animal models (15,32,(46)(47)(48)(49).…”

Section: Discussionmentioning

confidence: 99%

Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates

Richardson

Pillet

Bello

et al. 2013

J Virol

View full text Add to dashboard Cite

b Anti-adenovirus serotype 5 antibodies are capable of neutralizing adenovirus serotype 5-based vaccines. In mice and guinea pigs, intranasal delivery of adenovirus serotype 5-based vaccine bypasses induced adenovirus serotype 5 preexisting immunity, resulting in protection against species-adapted Ebola virus challenge. In this study, nonhuman primates were vaccinated with adenovirus serotype 5-based vaccine either intramuscularly or via the airway route (intranasally/intratracheally) in the presence or absence of adenovirus serotype 5 preexisting immunity. Immune responses were evaluated to determine the effect of both the vaccine delivery route and preexisting immunity before and after a lethal Ebola virus (Zaïre strain Kikwit 95) challenge. Intramuscular vaccination fully protected nonhuman primates in the absence of preexisting immunity, whereas the presence of preexisting immunity abrogated vaccine efficacy and resulted in complete mortality. In contrast, the presence of preexisting immunity to adenovirus serotype 5 did not alter the survival rate of nonhuman primates receiving the adenovirus serotype 5-based Ebola virus vaccine in the airway. This study shows that airway vaccination with adenovirus serotype 5-based Ebola virus vaccine can efficiently bypass preexisting immunity to adenovirus serotype 5 and induce protective immune responses, albeit at lower efficacy than that using an intramuscular vaccine delivery route.

show abstract

Section: Discussionmentioning

confidence: 99%

Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates

Richardson

Pillet

Bello

et al. 2013

J Virol

View full text Add to dashboard Cite

show abstract

“…During the past decade, a number of recombinant rabies vaccine candidates based on live attenuated RABV or recombinant viruses expressing RABV G (such as V-RG) have been developed as potential alternatives to current rabies vaccines (17,29,(32)(33)(34)(35). While some of the vaccine candidates generated protective immunity when administered via the i.m.…”

Section: Discussionmentioning

confidence: 99%

A Novel Rabies Vaccine Based on a Recombinant Parainfluenza Virus 5 Expressing Rabies Virus Glycoprotein

Chen

Zhou

Gao

et al. 2013

J Virol

View full text Add to dashboard Cite

8 PFU of rPIV5-RV-G showed a 50% survival rate, which is comparable to the 60% survival rate among mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE. This is first report of an orally effective rabies vaccine candidate in animals based on PIV5 as a vector. These results indicate that rPIV5-RV-G is an excellent candidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a potential vector for oral vaccines.

show abstract

“…Oral vaccine development using replication defective adenovirus, such as the vector we have tested, may be impeded by vector instability in the acidic environment of the stomach, through which it must pass to ensure antigen presentation and maximum exposure to and uptake by the antigen presenting cells of the intestine. Genomic DNA from adenovirus vector administered orally to mice is found in very limited amounts in the stomach, small intestines, and PP at the early time point of Day 4 (as compared to higher amounts found in the oral cavity) and is nearly not detectable after Day 10 [19].…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies using replication defective adenovirus as an oral vaccine have elicited strong transgene product-specific antibodies in serum and, in particular, mucosal secretions such as vaginal wash or saliva [4,18,19], even in the face of pre-existing immunity to the virus [20]. In our study, oral administration of AdC68gag can overcome pre-existing immunity to AdHu5, and it elicited a low gag-specific CD8 + T cell response in the spleen and blood at early time points but not in the GALT.…”

Section: Discussionmentioning

confidence: 99%

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut

Lin

Cun

Harris-McCoy

et al. 2007

Vaccine

View full text Add to dashboard Cite

Gut-associated lymphoid tissue (GALT) is the primary replication site for HIV-1, resulting in a pronounced CD4 + T cell loss in this tissue during primary infection. A mucosal vaccine that generates HIV-specific CD8 + T cells in the gut could prevent the establishment of founder populations and broadcasting of virus. Here, we immunized mice orally and systemically with a chimpanzee derived adenoviral vector expressing HIV gag (AdC68gag) and measured frequencies of gag-specific interferon-gamma (IFN-γ) producing CD8 + T cells in the GALT. A single oral administration was inefficient at eliciting responses in the mesenteric lymph nodes and Peyer's Patches, while a single intramuscular administration elicited strong systemic and detectable mucosal responses. The gagspecific CD8 + T cell responses were present in both acute and memory phases following intramuscular administration.

show abstract

A Chimpanzee-Origin Adenovirus Vector Expressing the Rabies Virus Glycoprotein as an Oral Vaccine against Inhalation Infection with Rabies Virus

Cited by 50 publications

References 30 publications

Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates

Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates

A Novel Rabies Vaccine Based on a Recombinant Parainfluenza Virus 5 Expressing Rabies Virus Glycoprotein

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut

Contact Info

Product

Resources

About